Page 3 - 09769810 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Susquehanna International Group LLP purchased a new stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Rating) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,307 shares of the company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned approximately 0.05% […]

Bolt Biotherapeutics (NASDAQ:BOLT – Get Rating)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 497.01% from the stock’s previous close. HC Wainwright […]

Bolt Biotherapeutics (NASDAQ:BOLT – Get Rating) and Endonovo Therapeutics (OTCMKTS:ENDVD – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Profitability This table compares Bolt Biotherapeutics and Endonovo Therapeutics’ […]

Bolt Biotherapeutics (NASDAQ:BOLT – Get Rating) and Nektar Therapeutics (NASDAQ:NKTR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability. Risk & Volatility Bolt Biotherapeutics has a beta of […]

Bolt Biotherapeutics (NASDAQ:BOLT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a $2.00 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 14.29% from the stock’s […]